MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis

被引：1
|
作者：
Goetz, Matthew P. [1 ]
Martin, Miguel [2 ,3 ]
Di Leo, Angelo [4 ]
Im, Seock-Ah [5 ]
Awada, Ahmad [6 ]
Forrester, Tammy [7 ]
Frenzel, Martin [7 ]
Cox, Joanne [8 ]
Barriga, Susana [9 ]
Toi, Masakazu [10 ]
Iwata, Hiroji [11 ]
Johnston, Stephen [12 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[3] Univ Complutense, Madrid, Spain
[4] Hosp Prato, Prato, Italy
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea
[6] Jules Bordet Inst, Brussels, Belgium
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Windlesham, Surrey, England
[9] Eli Lilly & Co, Madrid, Spain
[10] Kyoto Univ, Kyoto, Japan
[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[12] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT040
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [22] nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
    Hamilton, E.
    Cortes, J.
    Dieras, V.
    Ozyilkan, O.
    Chen, S-C
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Lu, Y.
    Bear, M. M.
    Johnston, E. L.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [24] Abemaciclib for treating patients with HR+, HER2-advanced/metastatic breast cancer in Spain: a real-world study
    Blancas, I.
    Fakhouri, W.
    Molero, A.
    Diaz-Cerezo, S.
    Haro, J. M.
    Faris, L. H.
    Sanchez-Bayona, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S59 - S60
  • [25] MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
    Goetz, Matthew P.
    Toi, Masakazu
    Campone, Mario
    Sohn, Joohyuk
    Paluch-Shimon, Shani
    Huober, Jens
    Park, In Hae
    Tredan, Olivier
    Chen, Shin-Cheh
    Manso, Luis
    Freedman, Orit C.
    Jaliffe, Georgina Garnica
    Forrester, Tammy
    Frenzel, Martin
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Di Leo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (32) : 3638 - +
  • [26] MONARCH 3: Updated time to chemotherapy and disease progression following abemaciclib plus aromatase inhibitor (AI) in HR+, HER2-advanced breast cancer (ABC)
    Huober, J.
    Martin, M.
    Johnston, S.
    Di Leo, A.
    Sohn, J.
    Andre, V. A. M.
    Martin, H. R.
    Hardebeck, M. C.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 163 - 163
  • [27] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [28] Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer that had exhibited primary or secondary resistance to prior endocrine therapy
    Foster, C.
    Pivot, X.
    Llombart-Cussac, A.
    Neven, P.
    Lin, Y.
    Kaufman, P. A.
    Sledge, Jr G. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 290
  • [29] Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2-advanced or metastatic breast cancer: A systematic review and meta-analysis.
    Altaf, Faryal
    Qureshi, Zaheer
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
12345